Trials in patients with dyslipidaemia or cardiovascular disease have shown no beneficial effects on 'hard' clinical end points, and increased rates of adverse effects, when niacin is added to statin therapy. These findings lead us to question whether niacin has a role in modern lipid-lowering strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/eht055.
O'Riordan, M. “If not dead, not healthy”: Niacin full results in HPS2-THRIVE aired at ACC. Theheart.org[online], (2013).
The AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255–2267 (2011).
The ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
Vogt, A., Kassner, U., Hostalek, U. & Steinhagen-Thiessen, E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr. Med. Res. Opin. 22, 417–425 (2006).
Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556–2564 (2011).
Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
Maher, V. M. et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274, 1771–1774 (1995).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Wierzbicki, A. Failure to THRIVE: the end for niacin?. Nat Rev Cardiol 10, 246–247 (2013). https://doi.org/10.1038/nrcardio.2013.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.48
